# OnCo record paper-polarix-polatuzumab-rchp-nejm-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-polarix-polatuzumab-rchp-nejm-2022/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-polarix-polatuzumab-rchp-nejm-2022" ;
  schema:name "POLARIX: swapping vincristine for the antibody-drug conjugate polatuzumab vedotin in first-line treatment of diffuse large B-cell lymphoma"@en ;
  schema:description "Replacing one chemotherapy drug in R-CHOP with a CD79b antibody-drug conjugate modestly reduced progression (2-year PFS 76.7% versus 70.2%) without changing survival or side effects."@en ;
  schema:url <https://onco.cc/key-papers/paper-polarix-polatuzumab-rchp-nejm-2022/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2115304>, <https://clinicaltrials.gov/study/NCT03274492> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2115304> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Tilly H, Morschhauser F, Sehn LH, et al." ;
  onco:related <https://onco.cc/roadmaps/lymphoma-roadmap/>, <https://onco.cc/key-papers/paper-polargo-polatuzumab-r-gemox-dlbcl-jco-2026/>, <https://onco.cc/trials/polar-bear/> ;
  onco:cancers <https://onco.cc/cancers/dlbcl/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/cd79b/>, <https://onco.cc/targets/cd20/> ;
  onco:drugs <https://onco.cc/drugs/polatuzumab-vedotin/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/vincristine/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:terms <https://onco.cc/terms/pfs/>, <https://onco.cc/terms/os/> ;
  onco:trials <https://onco.cc/trials/polarix/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-drug-pricing/>, <https://onco.cc/bottlenecks/b-biomarker-validation/> ;
  onco:journals <https://onco.cc/journals/nejm/> .